Publication:
EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer

Simple item page
dc.contributor.authorMartin, Vittoria
dc.contributor.authorZanellato, Elena
dc.contributor.authorFranzetti-Pellanda, Alessandra
dc.contributor.authorMolinari, Francesca
dc.contributor.authorMovilia, Alessandra
dc.contributor.authorPaganotti, Alessia
dc.contributor.authorDeantonio, Letizia
dc.contributor.authorDe Dosso, Sara
dc.contributor.authorAssi, Agnese
dc.contributor.authorCrippa, Stefano
dc.contributor.authorBoldorini, Renzo
dc.contributor.authorMazzucchelli, Luca
dc.contributor.authorSaletti, Piercarlo
dc.contributor.authorFrattini, Milo
dc.date.accessioned2019-02-28T09:24:25Z
dc.date.available2019-02-28T09:24:25Z
dc.date.issued2014
dc.description.abstractBackground: Combined chemoradiation therapy is the gold standard in the treatment of squamous cell anal cancer (SCAC). However, even if the response rate is very high, many patients eventually relapse or experience a recurrence, thus requiring an invasive surgical procedure that has severe side effects. Most SCAC tumors overexpress epidermal growth factor receptor (EGFR); therefore, it is reasonable to consider anti-EGFR drugs as a new treatment option, as demonstrated by anecdotal reports. Promising results obtained in other solid tumors, both squamous and non-squamous, have revealed that an increase in the EGFR gene copy number may predict the efficacy of anti-EGFR therapies, while the presence of mutations in downstream members of the EGFR pathway may confer resistance. These markers have been only sporadically considered in SCAC. Methods: We investigated the status of the EGFR gene using FISH and examined KRAS, BRAF, and PIK3CA hot-spots mutations using sequencing analysis in a cohort of 84 patients affected by SCAC. Results: Twenty-eight patients (34%) showed an increase in EGFR gene copy number due to amplification (4%) or to polysomy (30%). KRAS and PIK3CA gene mutations were found in 4 (5%) and 13 patients (16%), respectively. No mutations were found in the BRAF gene. Conclusions: The characterization of the EGFR pathway may help in identifying different subgroups of SCAC that have specific molecular features, which may have implications in what targeted therapies are used to treat each patient. Histol Histopathol 29, 513-521 (2014)es
dc.formatapplication/pdfes
dc.format.extent9es
dc.identifier.citationHistology and Histopathology, vol. 29, nº 4, (2014)
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/67959
dc.languageenges
dc.publisherF. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histologíaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectSquamous Cell Anal Canceres
dc.subjectEGFRes
dc.subjectKRASes
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes
dc.titleEGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal canceres
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Martin-29-513-521-2014.pdf
Size:
728.43 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.29, nº 4 (2014)